Urine 6-Bromotryptophan: Associations with Genetic Variants and Incident End-Stage Kidney Disease.

TitleUrine 6-Bromotryptophan: Associations with Genetic Variants and Incident End-Stage Kidney Disease.
Publication TypeJournal Article
Year of Publication2020
AuthorsSekula P, Tin A, Schultheiss UT, Baid-Agrawal S, Mohney RP, Steinbrenner I, Yu B, Luo S, Boerwinkle E, Eckardt K-U, Coresh JJ, Grams ME
Secondary AuthorsKӧttgen A
JournalSci Rep
Volume10
Issue1
Pagination10018
Date Published2020 06 22
ISSN2045-2322
Abstract

Higher serum 6-bromotryptophan has been associated with lower risk of chronic kidney disease (CKD) progression, implicating mechanisms beyond renal clearance. We studied genetic determinants of urine 6-bromotryptophan and its association with CKD risk factors and incident end-stage kidney disease (ESKD) in 4,843 participants of the German Chronic Kidney Disease (GCKD) study. 6-bromotryptophan was measured from urine samples using mass spectrometry. Patients with higher levels of urine 6-bromotryptophan had higher baseline estimated glomerular filtration rate (eGFR, p 

DOI10.1038/s41598-020-66334-w
Alternate JournalSci Rep
PubMed ID32572055
PubMed Central IDPMC7308283
Grant ListR21 DK112087 / DK / NIDDK NIH HHS / United States
UL1 RR025005 / RR / NCRR NIH HHS / United States
R01 HL086694 / HL / NHLBI NIH HHS / United States
U01 HG004402 / HG / NHGRI NIH HHS / United States
HHSN268201700002C / HL / NHLBI NIH HHS / United States
HHSN268201700001I / HL / NHLBI NIH HHS / United States
HHSN268201700004I / HL / NHLBI NIH HHS / United States
HHSN268201700004C / HL / NHLBI NIH HHS / United States
R01 HL087641 / HL / NHLBI NIH HHS / United States
HHSN268201700003I / HL / NHLBI NIH HHS / United States
HHSN268201700005C / HL / NHLBI NIH HHS / United States
HHSN268201700001C / HL / NHLBI NIH HHS / United States
HHSN268201700003C / HL / NHLBI NIH HHS / United States
HHSN268201700002I / HL / NHLBI NIH HHS / United States
HHSN268201700005I / HL / NHLBI NIH HHS / United States